Eledon Pharmaceuticals, Inc. (NasdaqCM: ELDN) was added to the Russell 2500 Index, reflecting its growth and market recognition. The company reported earnings results for multiple quarters in 2024 and 2025, highlighted clinical trials for its lead drug tegoprubart, and secured $49.999 million in funding in 2024 and $2.099993 million in 2025.

The kidney transplant rejection therapeutics market in the 7MM (US, EU4, UK, Japan) is projected to grow at a CAGR by 2034, with key developments including clinical trials by Biogen and Tract Therapeutics, rising transplant cases, and emerging therapies like MDR-101 and Tegoprubart.

DelveInsight's report on IgA nephropathy pipeline therapies highlights 30+ companies developing 30+ pipeline therapies for treatment. Key events include Novartis acquiring Chinook Therapeutics for $3.2 billion, positive Phase III trial results for iptacopan, and FDA approvals for drugs like tegoprubart and BCX9930. Clinical trials for drugs like TST004 and Sparsentan are advancing, with focus on targeting complement pathways and MASP2.

Eledon Pharmaceuticals is set to release Q1 2025 earnings results, with analysts expecting a loss of $0.28 per share, missing the consensus estimate. The company previously reported a loss of $0.64 per share in Q1 2024, while its stock has a market cap of $171.86 million and a negative PE ratio. Guggenheim recently assigned a 'buy' rating with a $9.00 price target.

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) announced the appointment of Deloitte & Touche LLP as its new independent registered public accounting firm, effective April 1, 2025. The change comes after the dismissal of Crowe LLP, effective April 1, 2025. Eledon's financial health is rated 'FAIR' by InvestingPro, with strong cash flow management. The company's stock has experienced significant volatility, declining 16.5% over the past week but maintaining a positive 64.5% return over the last year. Eledon also announced successful xenotransplantation using tegoprubart, an investigational drug, with a kidney transplant from a genetically modified pig to a human patient. The patient has been discharged and no longer needs dialysis. Eledon plans to release updated clinical trial results later this year.